Regenerative Medical Technology (RMTG) Invested Capital (2017 - 2026)

Regenerative Medical Technology has reported Invested Capital for 10 years, with the latest figure at -$20.3 million in Q2 2026.

• On a quarterly basis, Invested Capital fell 137.91% year-over-year to -$20.3 million in Q2 2026; TTM through Jun 2026 was -$20.3 million, a 137.91% decrease from a year earlier, with the FY2025 full-year figure at -$18.6 million, down 143.71% from the prior year.
• Invested Capital was -$20.3 million for Q2 2026 at Regenerative Medical Technology, down from -$16.4 million in the prior quarter.
• The five-year high for Invested Capital was $12.8 million in Q3 2023, with the low at -$20.3 million in Q2 2026.
• Average Invested Capital over 5 years is -$1.1 million, with a median of $1.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Invested Capital jumped 1989.08% in 2022, then slumped 324.36% in 2024.
• Over 5 years, Invested Capital stood at $11.1 million in 2022, then plunged by 116.2% to -$1.8 million in 2023, then plunged by 324.36% to -$7.6 million in 2024, then plunged by 143.71% to -$18.6 million in 2025, then dropped by 9.23% to -$20.3 million in 2026.
• The last three Invested Capital figures came in at -$20.3 million (Q2 2026), -$16.4 million (Q1 2026), and -$18.6 million (Q4 2025), per Business Quant data.